Cyclopharm Limited (AU:CYC) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cyclopharm Limited has announced a significant partnership with the US Veterans Administration, securing an interim agreement to supply Technegas, a diagnostic product for lung diseases, to 120 VA hospitals. This deal is a precursor to broader inclusion in the US Federal Supply Schedule, expected to enhance care for conditions such as COPD and pulmonary fibrosis in veterans. Concurrently, Cyclopharm has also received its first Technegas order from the US Department of Defense, marking a strategic advancement in the company’s expansion within the largest nuclear medicine market.
For further insights into AU:CYC stock, check out TipRanks’ Stock Analysis page.